India’s Granules will do a significant expansion of its API bulk drug site in Vishakhapatnam, and is getting substantial help from the International Finance…

China’s Kangmei Pharma, a company focused on oral traditional Chinese medicine, intends to pour $146 million into a healthcare industry fund.

Takeda says its new oral multiple myeloma drug Ninlaro is on course to become its biggest-ever cancer product.

Daiichi Sankyo licenses two abuse-deterrent painkillers from Inspirion to further its pain-management ambitions.

AstraZeneca has licensed diabetes drugs Byetta and Bydureon to 3SBio to kickstart sales growth in China.

China Resources Pharmaceutical Group will kick off its initial public offering in Hong Kong in the next few days, hoping to raise up to $2 billion for…

Piramal added to its run of healthcare acquisitions with a $175 million deal to buy five injectable pain drugs from Johnson & Johnson.

South Korean authorities are investigating allegations of insider trading ahead of Boehringer Ingelheim's decision to hand back hot-potato rights to a…

Financials